InsidersTradesSigma
Follow the 惠泰医疗 share price and the full insider trade history of the company, a publicly traded company based in China. Shares are quoted on the CN market, under the supervision of SSE / SZSE (CSRC). Operating in the Health Care sector, 惠泰医疗 has published 6 public disclosures. Market capitalisation: €29.7bn. The latest transaction was disclosed on 14 May 2026 (Purchase). Among the most active insiders: 赵宇翔. The full history is openly available.
6
Insider Decl.
n/a
Thresholds
€523,099
2 ops.
Buy Volume
€67m
4 ops.
Sell Volume
11Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 7,305 of 29,063 companies
63.9
score / 100
Value35
Quality93
FCF yld1.9%
Earn yld2.3%
EV/EBITDA33.5x
ROE31%
Gross mgn73%
Net mgn32%
Debt/EBITDA0.0x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 14 May 2026
Declarations6 total
6 of 6 declarations
关于 惠泰医疗
惠泰医疗是一家在医疗保健和制药领域运营的公司，在上海证券交易所上市。它专注于创新医疗解决方案的开发和商业化。